Geode Capital Management LLC decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,441,842 shares of the biotechnology company’s stock after selling 16,889 shares during the quarter. Geode Capital Management LLC owned 0.83% of Exelixis worth $74,231,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Public Employees Retirement Association of Colorado boosted its stake in shares of Exelixis by 3.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 53,942 shares of the biotechnology company’s stock valued at $1,640,000 after purchasing an additional 1,840 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Exelixis by 24.1% in the third quarter. Mackenzie Financial Corp now owns 10,116 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 1,963 shares during the period. Stifel Financial Corp boosted its stake in shares of Exelixis by 2.8% in the third quarter. Stifel Financial Corp now owns 72,974 shares of the biotechnology company’s stock valued at $1,768,000 after purchasing an additional 2,009 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Exelixis by 8.7% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 26,607 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 2,138 shares during the period. Finally, Swiss National Bank raised its holdings in Exelixis by 0.5% in the third quarter. Swiss National Bank now owns 489,200 shares of the biotechnology company’s stock valued at $11,853,000 after acquiring an additional 2,300 shares in the last quarter. 80.55% of the stock is owned by institutional investors and hedge funds.
Several analysts recently weighed in on EXEL shares. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, January 5th. SunTrust Banks reaffirmed a “buy” rating and issued a $38.00 target price on shares of Exelixis in a report on Thursday, December 21st. Cann reaffirmed a “buy” rating and issued a $40.00 target price on shares of Exelixis in a report on Thursday, March 8th. Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a report on Wednesday, January 17th. Finally, Stifel Nicolaus raised their target price on shares of Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. Exelixis has an average rating of “Hold” and an average target price of $34.10.
Shares of Exelixis, Inc. (EXEL) opened at $24.80 on Wednesday. Exelixis, Inc. has a 1-year low of $18.03 and a 1-year high of $32.50. The firm has a market cap of $7,354.35, a P/E ratio of 48.67, a price-to-earnings-growth ratio of 1.35 and a beta of 1.96.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. The company had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. During the same quarter last year, the company earned $0.12 earnings per share. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. research analysts anticipate that Exelixis, Inc. will post 0.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/exelixis-inc-exel-shares-sold-by-geode-capital-management-llc.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.